tiprankstipranks
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
US Market

Ionis Pharmaceuticals (IONS) Ownership - Who Owns Ionis Pharmaceuticals?

Compare
1,348 Followers

Ionis Pharmaceuticals (IONS) Ownership Overview

0.74%39.51%0.23%14.87%44.65%
0.23% Other Institutional Investors
14.87% ETFs
44.65% Public Companies and Individual Investors
The ownership structure of Ionis Pharmaceuticals (IONS) stock is a mix of institutional, retail, and individual investors. Approximately 54.60% of the company’s stock is owned by Institutional Investors, 0.74% is owned by Insiders, and 44.65% is owned by Public Companies and Individual Investors.
The ownership structure of Ionis Pharmaceuticals (IONS) stock is a mix of institutional, retail, and individual investors. Approximately 39.73% of the company’s stock is owned by Institutional Investors, 0.74% is owned by Insiders, and 14.87% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Feb 03, 2025
Patrick O'neil
Evp Clo & Gc
xxxxxxxxxxxxx
$45681
Feb 03, 2025
Brett Monia
Director
xxxxxxxxxxxxx
$429570
Feb 03, 2025
Frank C. Bennett
Evp, Chief Scientific Officer
xxxxxxxxxxxxx
$43074
Feb 03, 2025
Elizabeth Hougen
Evp, Finance & Cfo
xxxxxxxxxxxxx
$49391

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2024
xxxxxxxxxxxxx
$35843089

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
13,863,648Institution8.78%430,327,634
12,372,821Institution7.84%384,052,364
11,778,759Institution7.46%365,612,679
5,733,312Institution3.63%177,962,004
5,300,000Institution3.36%164,512,000
4,396,443Institution2.78%136,465,591
3,248,863Institution2.06%100,844,708
2,954,743Institution1.87%91,715,223
2,720,265Institution1.72%84,437,026
2,603,534Institution1.65%80,813,695

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
12,372,821Institution7.84%384,052,364
11,778,759Institution7.46%365,612,679
5,733,312Institution3.63%177,962,004
5,300,000Institution3.36%164,512,000
2,954,743Institution1.87%91,715,223
2,720,265Institution1.72%84,437,026
2,405,080Institution1.52%74,653,683
2,324,474Institution1.47%72,151,673
2,163,676Institution1.37%67,160,503
1,754,349Institution1.11%54,454,993

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,789,271Institution3.03%167,432,914
3,819,647Institution2.42%133,534,859
2,548,019Institution1.61%77,332,377
2,387,221Institution1.51%83,457,246
2,167,510Institution1.37%75,776,150
1,001,250Institution0.63%30,387,938
910,071Institution0.58%28,248,604
843,135Institution0.53%26,170,910
759,543Institution0.48%23,052,130
514,091Institution0.33%15,957,385

FAQ

Who Owns Ionis Pharmaceuticals (IONS)?
According to the latest TipRanks data, approximately 0.23% of the company's stock is held by institutional investors, 0.74% is held by insiders, and 44.65% is held by retail investors.
    What percentage of Ionis Pharmaceuticals (IONS) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 0.23% of Ionis Pharmaceuticals (IONS) stock is held by institutional investors.
      What percentage of Ionis Pharmaceuticals (IONS) stock is held by retail investors?
      According to the latest TipRanks data, approximately 44.65% of Ionis Pharmaceuticals (IONS) stock is held by retail investors.
        Who owns the most shares of Ionis Pharmaceuticals (IONS)?
        Vanguard owns the most shares of Ionis Pharmaceuticals (IONS).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis